Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): A systematic analysis of expert opinion

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 206-209

  Lowe, F C ^a   Batista, J ^b   Berges, R ^c   Chartier Kastler, E ^d   Conti, G ^e   Desgrandchamps, F ^f   Dreikorn, K ^g   O'Leary, M ^h   Perez, M ⁱ   Speakman, M ^j   Trachtenberg, J ^k   Tubaro, A ^l   Meesen, B ^m   Smets, L ^m   Stoevelaar, H ⁿ  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b FUNDACIÓ PUIGVERT   (Spain)

^c PAN Klinik am Neumarkt   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SANT ANNA HOSPITAL   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g Zentralkrankenhaus St Juergenstrasse   (Germany)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ Saõ Paulo Santa Casa Hospital   (Brazil)

^j TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^k UNIVERSITY OF TORONTO   (Canada)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m Ismar Healthcare ^*  (Belgium)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Benign prostatic hyperplasia; Disease progression; Lower urinary tract symptoms; Risk factors

Indexed keywords

ARTICLE; CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FLOW RATE; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MICTURITION; PATIENT CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SYMPTOM; URINARY TRACT DISEASE; UROLOGY;

DISEASE PROGRESSION; HUMANS; LOGISTIC MODELS; MALE; PROBABILITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK; RISK FACTORS; UROLOGIC DISEASES;

EID: 29944438602     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500806     Document Type: Article

References (14)

1. Jacobsen SJ et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997; 158: 481-487.
2. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-563.
3. Roehrborn CG et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-480.
4. McConnell JD et al. Baseline measures predict the risk of benign prostatic hyperplasia clinical progression in placebo-treated patients. J Urol 2003; 169 (Suppl): 332 (Abstract 1287).
5. Roehrborn CG, Boyle P, Nickel JC. PSA is a significant predictor of objective parameters in men at risk of BPH progression. J Urol 2003; 169 (Suppl): 364-365 (Abstract 1362).
6. McConnell JD et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
7. Jimenez-Cruz F. Identifying patients with lower urinary tract symptoms/ benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 6-12.
8. Kaplan SA et al. Baseline symptoms, uroflow, and post-void residual urine as predictors of BPH clinical progression in the medically treated arms of the MTOPS trial. J Urol 2003; 169 (4 Suppl): 332-333 (Abstract 1289).
9. Speakman MJ et al. Integrating risk profiles in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia. A systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 61 (Abstract 233).
10. Brook RH et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53-63.
11. Meesen B. LUTS/BPH progression A literature review on risk factors for progression and impact of medical therapy on progression. Lier (Belgium), ISMAR Healthcare. 2003.
12. Lowe F et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia; a systematic analysis of expert opinion. Eur Urol Suppl 2004; 3: 39 (Abstract 147).
13. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: Results of an international survey. Eur Urol 2002; 41: 490-496.
14. McNicholas T. LUTS, the case is altered. Eur Urol Suppl 2002; 1: 28-35.